Event-Driven Stocks

Day One Biopharmaceuticals, Inc.

DAWN

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 4 good● 3 warningdetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$158.2M$131.2M$0$0——
Operating income−$127.8M−$217.3M−$206.1M−$146.9M−$72.7M−$13.8M
Net income−$107.3M−$95.5M−$188.9M−$142.2M−$72.8M−$40.5M
Total assets$507.8M$582.8M$376.0M$349.1M$289.8M$45.7M
Total liabilities$66.7M$80.0M$29.5M$17.0M$8.7M$2.2M
Equity$441.2M$502.8M$346.5M$332.0M$281.1M−$54.2M
EPS (diluted)$-1.04$-1.02$-2.37$-2.17$-4.62$-7.33
Shares out.101.4M87.4M73.6M62.0M62.0M5.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−80.8%
Net margin
−67.8%
Return on equity
−24.3%
Return on assets
−21.1%
Return on capital (ROCE)
−28.6%
Liabilities / assets
13.1%
Debt / equity
0.15×
Book value / share
$4.35
Revenue growth (YoY)
20.6%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
6.50safe
Accruals / assets
−0.7%clean
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
67
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 67Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 3 warning● 4 good
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)
  • Altman Z″ in the safe zone

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Apr 15, 20266.6M5.4-9.1%
Mar 31, 20267.2M2.2-10.6%
Mar 13, 20268.1M1.0-20.3%
Feb 27, 202610.2M5.9-1.3%
Feb 13, 202610.3M5.2+0.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (3)